Finerenone cuts CV risk in patients with diabetes and kidney disease
AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.
The first-in-class non-steroidal mineralocorticoid receptor antagonist finerenone improves cardiovascular outcomes in patients with type 2 diabetes and early-stage kidney disease, a major trial shows.
The multinational FIGARO-DKD trial, which included Australian patients, reduced the occurrence of its primary endpoint – cardiovascular death, non-fatal myocardial infarction and hospitalisation for heart failure – by a statistically significant 13%.
“I’d like to emphasise that this was primarily driven by a 29% reduction in hospitalisation for heart failure,” chief investigator Professor Bertram Pitt, from the University of Michigan Medical School, US, told the ESC Congress 2021.
